Markus Munder
Mainz, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 23, 2025
Clonal diseases in the border zone rheumatology/hematology
Journal: Zeitschrift fur Rheumatologie
Published: June 13, 2025
Case Report: Late-onset primary hemophagocytic lymphohistiocytosis leading to the diagnosis of Griscelli syndrome type 2 in a young woman with phenotypically inapparent partial albinism.
Journal: Frontiers in immunology
Published: April 01, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.
Journal: Annals of hematology
Published: December 25, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: September 30, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 16, 2024
Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone.
Journal: EJHaem
Published: May 10, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Journal: Hematology (Amsterdam, Netherlands)
Published: February 26, 2024
Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?
Journal: Journal of clinical medicine
Published: December 13, 2023
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Journal: Leukemia
Published: December 01, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Journal: Leukemia
Published: September 28, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 27, 2023
Last Updated: 09/26/2026